COSM News & Events

The company said: "At current trading levels, the Company's shares trade at a significant discount to reported book value, and management believes the Company's market capitalization does not fully reflect the intrinsic value of its diversified asset base and strong operating performance. While management recognizes the long-term strategic value of its real estate and digital asset holdings, it is also evaluating potential monetization options, subject to market conditions, that could generate substantial capital to address the current valuation disconnect and support key corporate priorities, including acquisitions, technology investments, debt reduction, and returning capital to shareholders, including share repurchases."

Cosmos Health provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. "Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions. Management believes the Company is progressing toward sustained profitability as revenue continues to grow, scale efficiencies crystallize, and margins improve. The war in the Middle East and recent geopolitical turmoil have had a negligible impact on the Company's operations. The Company expects record-breaking growth to continue at a strong pace as it advances toward sustained profitability."

Cosmos Health announced that it has entered into a Letter of Intent, LOI, through its wholly owned subsidiary CosmoFarm S.A., with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market. The term of the LOI is ninety days from March 6, 2026. The network currently generates approximately EUR 10 million in annual gross revenue and serves a broad base of pharmacy customers, supplying both pharmaceutical and para-pharmaceutical products.

Cosmos Health announced a significant expansion of its United Kingdom retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4%, is now available through Tesco.